Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

AVR Anteris Technologies Global Corp. SEC Filings & Insider Trading Activity 2026

company
CIK 201151464 filings
Russell 2000

AVR at a glance

Anteris Technologies Global Corp. (AVR, SEC CIK 2011514) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as October 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Anteris Technologies Global Corp. (AVR) reported revenue of $1.9 million (down 29.2% from FY2024) and a net loss of $94.1 million. Diluted EPS was -$2.55.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Anteris Technologies Global Corp. (AVR) shares worth $102.1 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by L1 Capital Pty Ltd on October 6, 2026 of 272,695 shares at $7.18 per share.
  • In the last 90 days, AVR insiders reported 5 open-market purchases ($11.7M) and 1 open-market sale ($69K) on Form 4, a net purchase of $11.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.9M
−29.2% vs prior year
Insiders · 90 days
5 buys · 1 sell
Net +$11.6M
13F holders
23 funds
$102.1M · −2 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $519K, up 21% YoY from $429K, driven by higher 4C tissue-product sales
  • Gross margin percentage not disclosed, described as generally consistent YoY
  • Operating loss $29.8M vs $22.3M YoY, operating margin -5,749% vs -5,189%
  • Cash, equivalents and restricted cash $236.3M; operating cash outflow $72.4M for nine months
  • Financing provided $298.4M, including $308.6M net stock proceeds; ongoing losses and additional funding needs expected

Risk Factors

  • Regulatory risk: PARADIGM Trial approval under FDA IDE could be revoked
  • Clinical risk: PARADIGM Trial may be unsuccessful despite FDA authorization
  • Approval risk: DurAVR THV System may not receive FDA PMA
  • Compliance risk: FDA may impose costly post-market testing or controls after PMA
  • Revenue risk: approval delays could prevent revenue generation or profitability

AI summary of the AVR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 2026 reporting period covered by the filed Form 10-Q and ASX quarterly disclosure
  • Related-party payments totaled US$576,000, including executive salaries and non-executive director fees

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Form 10-Q filed with ASX on November 10, 2026, U.S. time

Item EX-99.2: Item EX-99.2

  • Q3 2026 operating cash outflows $22.9M, highlighting substantial funding needs during pivotal-trial execution
  • R&D expense $21.3M, driven by PARADIGM enrollment, manufacturing scale-up, quality validation and expanded clinical staffing
Filed Sep 23, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Supply and quality agreement extended through December 31, 2026, or earlier replacement agreement execution
  • Harvey Industries Group remains a key supplier or quality counterpart under unchanged existing terms
Filed Sep 17, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Contingent stock awards require shareholder approval, creating potential dilution and governance risk for investors
  • Wayne Paterson awarded 1,200,000 options and 800,000 PSUs; David St Denis awarded 414,000 options and 485,000 PSUs

AI summaries of AVR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AVR

Don't miss the next AVR filing

  • Alerts as it files. A push when AVR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AVR, by share count.
  • Ask anything. An AI agent that reads every AVR filing and answers with sources.

AVR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
L1 Capital Pty LtdBuyOct 6, 2026$7.18
L1 Capital Pty LtdBuyOct 5, 2026$7.51
L1 Capital Pty LtdBuyOct 2, 2026$7.78
L1 Capital Pty LtdBuyOct 1, 2026$7.60
L1 Capital Pty LtdBuySep 30, 2026$7.72
Moen BrentASep 11, 2026-
L1 Capital Pty LtdSellAug 28, 2026$8.83
St Denis DavidMAug 19, 2026$5.65

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.7M$1.9M
Operating Income--$78.4M-$93.9M
Net Income--$76.3M-$94.1M
Op. Margin--2899.4%-4908.2%
Net Margin--2822.5%-4921.3%
Balance Sheet
Total Assets-$80.7M$23.0M
Equity$18.9M$62.8M-$93K
ROE--121.6%101230.1%
Per Share
EPS-$-3.68$-2.55
Cash Flow
Operating CF--$61.2M-$77.8M
CapEx-$2.3M$2.0M

Source: XBRL data in Anteris Technologies Global Corp. (AVR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AVR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AVR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$102.1M
Q2 202625$192.6M
Q1 202624$72.2M
Q4 202517$28.3M
Q3 202517$29.9M
Q2 202516$12.8M
Q1 202514$3.7M
Q4 20243$6.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 139 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AVR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
10-QNov 10, 2026Analysis
4Oct 8, 2026--
4Oct 6, 2026--
4Oct 1, 2026--
8-KSep 23, 2026Analysis-
8-KSep 17, 2026Analysis-
4Sep 16, 2026--
8-KSep 8, 2026Analysis-
4Sep 1, 2026--
4Aug 20, 2026--
8-KAug 12, 2026Analysis-
4Aug 12, 2026--
10-QAug 11, 2026Analysis
4Aug 10, 2026--
SC 13GAug 6, 2026-
4Aug 6, 2026--
4Aug 4, 2026--
8-KAug 3, 2026Analysis-
8-KJul 31, 2026Analysis-
4Jul 31, 2026--
4Jul 29, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jun 9, 2026-

Related Health Care companies

All Health Care →

AVR SEC filings: frequently asked questions

Are AVR insiders buying or selling?

In the last 90 days, Anteris Technologies Global Corp. (AVR) officers, directors and 10% owners reported 5 open-market purchases worth $11.7 million by 1 insider and 1 open-market sale worth $68,874 by 1 insider on Form 4, a net purchase of $11.6 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold AVR stock?

As of September 30, 2026, the largest Anteris Technologies Global Corp. (AVR) holders among the 13F filers tracked by SignalX were BlackRock ($42.4 million), State Street Corp ($15.2 million), Citadel Advisors LLC ($7.9 million), Vanguard Capital Management LLC ($7.1 million), Vanguard Portfolio Management LLC ($5.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AVR's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Anteris Technologies Global Corp. (AVR) reported revenue of $1.9 million (down 29.2% from FY2024) and a net loss of $94.1 million. Diluted EPS was -$2.55. The figures come from the XBRL data in the 10-K.

What did AVR report in its latest 8-K?

Anteris Technologies Global Corp. (AVR) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 reporting period covered by the filed Form 10-Q and ASX quarterly disclosure.

What are the latest AVR SEC filings?

Anteris Technologies Global Corp. (AVR) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on October 8, 2026.

What is AVR's SEC CIK number?

Anteris Technologies Global Corp. (AVR)'s SEC Central Index Key (CIK) is 2011514. EDGAR lists every AVR filing under that number.

Ask anything about AVR

The research agent reads AVR's filings, financials, insider trades and 13F holders, then answers with sources.